| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_133a01184929f0954e1e874d7d5caaeb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a722430091b8d44ccfa87c9759b804f3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-282
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-282
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-51 |
| filingDate |
2016-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09ecbc38e7bddd006aeec0998bc61973
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e6d9e45754d928d9978b0e4e172f988
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88353cf850695b12244e60470226b8a9 |
| publicationDate |
2017-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2017037292-A1 |
| titleOfInvention |
Combination of a dhodh inhibitor and a her inhibitor for use in the treatment of cancer |
| abstract |
The present disclosure provides method of treating a cancer patient comprising administering a therapeutically effect amount of a DHODH inhibitor and a therapeutically effective amount of an inhibitor of a HER receptor, for example an inhibitor of at least HER2. Also provided is a combination therapy comprising a HER inhibitor and a DHODH inhibitor for use in the treatment of cancer and use of a HER inhibitor and a DHODH inhibitor in the manufacture of a combination therapy for the treatment of cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11382903-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10849899-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019012030-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017184086-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10682353-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11311548-B2 |
| priorityDate |
2015-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |